Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal
Eli Lilly has once again returned to the M&A table, striking a $2.875bn agreement to buy autoimmune and allergic disease…
01 Sep 2026
PharmaEssentia’s Besremi receives FDA approval for ET
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET). This marks the first FDA-approved treatment for ET in nearly…
01 Sep 2026
Kazia closes oversubscribed offering to fund paxalisib’s clinical development
Kazia Therapeutics has closed an oversubscribed public offering that could provide the company with up to $120m in gross proceeds if all milestone-linked warrants are exercised, aimed primarily at funding…
31 Aug 2026
Teva Pharmaceuticals to acquire BioXcel assets for up to $125m
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m. The agreement arises as part of…
29 Aug 2026
ESC 2026: Statins show worth despite emergence of PCSK9 inhibitors
A type of statin significantly reduces the risk of major cardiovascular events in elderly patients, demonstrating their continued importance despite the rising use of PCSK9 inhibitors in the past decade.…
28 Aug 2026
Lilly’s Mounjaro wins US label expansion for cardiovascular risk reduction
The US Food and Drug Administration (FDA) has approved Eli Lilly’s blockbuster type 2 diabetes therapy, Mounjaro (tirzepatide), as a treatment for cardiovascular risk reduction in patients with the cardiometabolic…
28 Aug 2026
FDA approves Priovant’s rare autoimmune therapy Lisraya in indication first
Priovant Therapeutics has secured approval from the US Food and Drug Administration (FDA) for its oral therapy Lisraya (brepocitinib) in a rare autoimmune disease called dermatomyositis, becoming the first targeted…